Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CD371-YSNVZIL-18 CAR T cells |
| Synonyms | |
| Therapy Description |
CD371-YSNVZIL-18 CAR T cells are T-lymphocytes engineered to express IL-18 and a chimeric antigen receptor (CAR) that targets CLEC12A (CD371), which potentially induce increased antitumor immune response and cytotoxicity against CLEC12A (CD371)-expressing tumor cells (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CD371-YSNVZIL-18 CAR T cells | CD371-specific/YSNVz/IL-18 CAR T-cells | CD371-YSNVZIL-18 CAR T cells are T-lymphocytes engineered to express IL-18 and a chimeric antigen receptor (CAR) that targets CLEC12A (CD371), which potentially induce increased antitumor immune response and cytotoxicity against CLEC12A (CD371)-expressing tumor cells (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06017258 | Phase I | CD371-YSNVZIL-18 CAR T cells | A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia | Recruiting | USA | 0 |